Results 211 to 220 of about 1,382,625 (239)

Tumor organoid-immune cell co-culture systems for precision oncology. [PDF]

Front Cell Dev Biol
Cai L, Xiao Y, Xie F, Yang Z.
europepmc   +1 more source

Extracellular Vesicles‐Based Biological Macromolecule Delivery Systems: Biogenesis, Characterization, and Emerging Clinical Applications

Biotechnology and Bioengineering, EarlyView.
ABSTRACT Extracellular vesicles (EVs) are nanoscale membrane‐bound structures that play a pivotal role in intercellular communication by transporting bioactive molecules, including proteins, lipids, nucleic acids, and organelles, between cells. Originating from the endosomal pathway, EVs reflect the physiological and pathological status of their parent
Emine İncilay Torunoğlu, Zeynep Betül Sarı, Muhammed Emin Sarı, Erdi Can Aytar   +3 more
wiley   +1 more source

Rethinking PDAC: from immunological silence to therapeutic opportunity. [PDF]

Front Immunol
Kali SK, Ramesh RPG, Alam A, Fernandez-Cabezudo MJ, Al-Awadhi AM, Kishore U, Al-Ramadi BK.   +6 more
europepmc   +1 more source

A nanoplatform that induces dual‐amino acid deprivation to reverse tumor immunosuppression and enhance metabolic immunotherapy

BMEMat, EarlyView.
ZIF‐8‐based nanoparticles co‐delivering CB‐839 (glutaminase inhibitor) and 1‐MT (IDO1 inhibitor), dual‐targeting glutamine/tryptophan metabolism to induce immunogenic cell death, activate STING, block kynurenine production, reverse immunosuppression, and enhance cancer immunotherapy to suppress primary/distant tumors.
Wenli Ning, Yunhan Sun, Mingyang Li, Shilu Liu, Fangjie Yi, Hongfei Wang, Ruibing Bai, Dongdong Liu, Fen Zhao, Guiqiang Zhang, Xiao Fu   +10 more
wiley   +1 more source

Donor NKG2A/NKG2C Immunophenotype Influences the GMP-Compliant Manufacturing Potential of NK Cells for Adoptive Immunotherapy. [PDF]

Cancers (Basel)
Meseguer R, Aguilar C, Amat P, Larrea L, Bonora A, Chorão P, Boix F, Piñana JL, Guerrero R, Montesinos P, Vera B, Planelles D, Luis M, Poveda JL, De la Rubia J, Querol S, Arbona C, Guerreiro M, Solano C.   +18 more
europepmc   +1 more source

Tackling cancer stemness with nanotechnology in the era of precision medicine

BMEMat, EarlyView.
Precise customization of nanoparticles (NPs) enables active targeting of cancer stem cells (CSCs), thereby improving drug delivery and therapeutic efficacy. NP‐based probing enhances CSC detection through imaging and liquid biopsy, whereas diverse therapeutic payloads improve therapeutic outcomes.
Shaolei Guo, Shun Yao, Lihui Meng, Chunyuan Chen, Yuechu Lucinda Lu, Rong Lu, Kashif Rafiq Zahid, Umar Raza, Qingzhi Wu, Wenli Chen   +9 more
wiley   +1 more source

Natural killer cells at the interface of tumor immune escape and immunotherapy resistance in endometrial cancer. [PDF]

Front Immunol
Poggi A, Bruno V, Di Spirito A, Mortara L, Baci D.   +4 more
europepmc   +1 more source

Quercetin‐zinc coordination polymer coated CaCO3 nanoparticles potentiate radiotherapy through reprogramming tumor immunosuppression

BMEMat, EarlyView.
Synthesis of QZCaCO3‐PEG to synergistically enhance the immunogenicity of radiotherapy through concurrent Zn2+‐induced cancer cell pyroptosis and Que‐mediated hypoxia amelioration through sequentially suppressing TGF‐β secretion and ECM deposition. Abstract Radiotherapy has demonstrated broad applications in treating solid tumors, but the hostile tumor
Chunjie Wang, Hengze Ding, Yu Hao, Honglin An, Ziliang Dong, Minming Chen, Yujie Zhu, Quguang Li, Bin Huang, Liangzhu Feng   +9 more
wiley   +1 more source

From Breakthrough to Access: How Biotechnology and Artificial Intelligence are Reshaping the Scalability and Precision of Cancer Immunotherapy. [PDF]

Iran J Biotechnol
Jahangiri B, Asadollahi E, Zomorodipour A.   +2 more
europepmc   +1 more source

Outcomes of immunotherapy in medulloblastoma: a systematic review. [PDF]

Oncologist
Fontão P, Viana-Pereira M, Pinto-Ribeiro F, Junqueira T, Reis RM.   +4 more
europepmc   +1 more source